
Dyne Therapeutics (NASDAQ:DYN) announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold and cleared its Investigational New Drug (IND) application to initiate a clinical trial of its drug DYNE-25.
The Phase 1/2 clinical trial will investigate DYNE-251 in patients with Duchenne muscular dystrophy (DMD), dosing is expected to begin in mid-2022.